Rheumatoid arthritis

ASRT Class Action Alert: Stockholders with Significant Losses in Assertion Holdings, Inc. Should Contact Robbins LLP for Information About the Class Action Lawsuit Against the Company

Retrieved on: 
Thursday, January 25, 2024
Patient, LLP, Person, SAN, Spectrum Pharmaceuticals, Rheumatoid arthritis, ASRT, Risk, Sale, Integration, Spectrum, Acquisition, Suppository, FDA, News

Assertio is a commercial pharmaceutical company that purportedly offers

Key Points: 
  • Assertio is a commercial pharmaceutical company that purportedly offers
    differentiated products to patients utilizing a non-personal promotional model.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What is this Case About: Assertio Holdings, Inc. (ASRT) Allegedly Misled Investors Regarding its Reliance on Indocin and Integration of Spectrum Pharmaceuticals, Inc.
  • In July 2023, Assertio acquired Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology, along with Spectrum’s injection asset Rolvedon.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Estee, VNET, and Assertio and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, January 25, 2024
Learning, Facility, Patient, EL, Adjustment, Spectrum Pharmaceuticals, Rheumatoid arthritis, ASRT, P.C, Complaint, Executive, Risk, Sale, Spectrum, Food, Acquisition, EPS, Suppository, FDA, News, Cayman, Defendant, Cryptocurrency

The filed complaint alleges that defendants misled investors with unrealistic and materially false statements about market demand Estee’s products and its inventory levels.

Key Points: 
  • The filed complaint alleges that defendants misled investors with unrealistic and materially false statements about market demand Estee’s products and its inventory levels.
  • As a result, the price of Estee stock declined from $245.22 per share on May 2, 2023 to $202.70 per share on May 3, 2023.
  • On this news, the Company’s share price fell $0.20, or 3.2% on February 13, 2023, on unusually heavy trading volume.
  • For more information on the Assertio class action go to: https://bespc.com/cases/ASRT

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Retrieved on: 
Wednesday, January 24, 2024
Magnetic resonance, Antigen presentation, Patient, Chronic obstructive pulmonary disease, IP, MRI, Inflammatory bowel disease, Pharmacokinetics, Rheumatoid arthritis, Asthma, Fatigue, Joint stiffness, IBD, API, HCQ, Cannabidiol, COPD, Quality of life, Plasma, NDA, FDA, Pain, Lupus erythematosus, Inflammation, Biomarker, Epilepsy, Magnetic resonance imaging, Hydroxychloroquine, Pharmaceutical industry

The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.

Key Points: 
  • The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.
  • Chief Scientific Officer of Incannex, Dr. Mark Bleackley, said; “Commencing dosing in the Phase 2 clinical trial in patients with RA is an exciting milestone for the development of IHL-675A.
  • Millions of people are affected by pain associated with rheumatoid arthritis despite the available treatment options.
  • Overview of Results from Phase 1 Clinical Trial Assessing Tolerability, Safety, and Pharmacokinetics of IHL-675A in Healthy Volunteers
    In 2022 and 2023, Incannex undertook a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of IHL-675A.

ASSERTIO HOLDINGS, INC. (NASDAQ: ASRT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Assertio Holdings, Inc.

Retrieved on: 
Monday, January 22, 2024
Action Replay, Patient, Spectrum Pharmaceuticals, Rheumatoid arthritis, ASRT, Complaint, Risk, Sale, District court, Court, Spectrum, Advertising, Acquisition, News, Defendant, Security (finance)

If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.

Key Points: 
  • If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 5, 2024.
  • If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Dollar General, Estee, VNET, and Assertio and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, January 21, 2024
Dollar General, Class, Risk, Sale, Theft, Complaint, Growth, Learning, Spectrum Pharmaceuticals, ASRT, P.C, Spectrum, Cayman, Defendant, Facility, Executive, Acquisition, Patient, Dollar, EL, Adjustment, Rheumatoid arthritis, Food, EPS, Suppository, FDA, News, Cryptocurrency

Then, on March 16, 2023, Dollar General revealed, among other things, that it missed its prior annual net sales guidance by approximately $140 million.

Key Points: 
  • Then, on March 16, 2023, Dollar General revealed, among other things, that it missed its prior annual net sales guidance by approximately $140 million.
  • On this news, the price of Dollar General common stock fell nearly 3%.
  • Thereafter, on June 1, 2023, Dollar General reported first quarter of 2023 revenue of $130 million below analysts’ estimates.
  • On, January 3, 2024, Assertio issued a press release announcing that Defendant Peisert was stepping down from his role as the Company's CEO.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Assertio Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – ASRT

Retrieved on: 
Thursday, January 18, 2024
Pomerantz, Patient, Person, Prior, Adjustment, Ext, Rheumatoid arthritis, Complaint, Risk, Sale, District court, Court, Spectrum, Food, Acquisition, EPS, Suppository, FDA, Action Replay, News, Pharmaceutical industry

NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT).

Key Points: 
  • NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT).
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways

Retrieved on: 
Wednesday, January 24, 2024
Pharmaceutical, Health, Oncology, Other Health, Entrepreneurship, Vitiligo, Patient, Incyte, Therapy, Rheumatoid arthritis, JAK, Third Rock Ventures, Molecular biology, Pharmacology, Cancer, Medicine, Drug discovery, FGFR, Cholangiocarcinoma, Ruxolitinib, Non-small-cell lung cancer, COVID-19, Atopic dermatitis, PARP1, FDA, Polycythemia, Eli Lilly and Company, Medicinal chemistry, Drug, EVP, GPH, CNS, Pharmaceutical industry

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.
  • Synnovation was founded by a world-class medicinal chemistry team with a track record of developing best-in-class therapeutics.
  • Proceeds will fund the advancement of the company’s clinical and preclinical pipeline, including SNV1521 and SNV4818, as well as additional programs.
  • The company’s lead program, SNV1521, is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.

Calluna Pharma Launches and Announces EUR 75 Million Series A Financing to Develop Novel Therapies for Inflammatory and Fibrotic Diseases

Retrieved on: 
Tuesday, January 23, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Phospholipid, Pharma, Patient, Therapy, Damage-associated molecular pattern, DAMP, Idiopathic pulmonary fibrosis, Complementarity, Rheumatoid arthritis, Asthma, Scleroderma, Immune system, MBA, Chronic kidney disease, Disease, EUR, Doctor of Philosophy, General partnership, Pharmaceutical industry

Calluna has raised EUR 75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53, and Investinor.

Key Points: 
  • Calluna has raised EUR 75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53, and Investinor.
  • Calluna is developing novel therapies that harness the transformative potential of the body's immune system.
  • As a result, Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases.
  • The Company is raising further financing to develop its pipeline to multiple key clinical milestones over the next 2.5 years.

ASRT Stock News: Shareholders Should Contact Robbins for Information About the Assertio Holdings, Inc. Securities Class Action

Retrieved on: 
Thursday, January 18, 2024
Class Action Lawsuit, Professional Services, Legal, Patient, LLP, Person, Spectrum Pharmaceuticals, Rheumatoid arthritis, ASRT, Risk, Sale, Integration, Spectrum, Acquisition, Suppository, FDA, News

Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.

Key Points: 
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What is this Case About: Assertio Holdings, Inc. (ASRT) Allegedly Misled Investors Regarding its Reliance on Indocin and Integration of Spectrum Pharmaceuticals, Inc.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Assertio Holdings, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.

New Study Finds People With Inflammatory Arthritis Are More Likely To Seek Mental Health Care

Retrieved on: 
Wednesday, January 24, 2024
Anxiety, Psoriatic arthritis, Rheumatoid arthritis, Ankylosing spondylitis, Inflammatory arthritis, Research, Disease, Conditional sentence, Diagnosis, Depression, Pharmaceutical industry

A recent study conducted by a team of scientists at Arthritis Research Canada has found a link between IA and the need for mental health treatment and medication.

Key Points: 
  • A recent study conducted by a team of scientists at Arthritis Research Canada has found a link between IA and the need for mental health treatment and medication.
  • This research aimed to describe patterns of depression and anxiety health care before and after a diagnosis among people with IA, including: ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis.
  • "The results of this study are revealing, but this is only a starting point," said Dr. Alyssa Howren, Research Trainee at Arthritis Research Canada.
  • "We need additional research to investigate alternative explanations as to why people with inflammatory arthritis have a higher requirement for mental health care and medication."